SCHEMBL15205193

SCHEMBL15205193

Clc1cc2cc[nH]c2nc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 5/20 0.39
PRKCI P41743 2/20 0.39
CDK8 P49336 1/20 0.39
CSNK2A1 P68400 2/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CG P48736 2/20 0.38
AHR P35869 3/20 0.38
NUDT1 P36639 2/20 0.38
CMA1 P23946 1/20 0.38
F7 P08709 1/20 0.38
LTA4H P09960 1/20 0.38
F3 P13726 1/20 0.38
NR4A2 P43354 1/20 0.38
RIPK1 Q13546 3/20 0.37
PIK3R1 P27986 1/20 0.35
BRD4 O60885 2/20 0.33
FGFR1 P11362 2/20 0.33
KDR P35968 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31398506 0.79 CSNK2A1 (0.44) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL23147918 0.79 AXL (0.37) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL1565481 0.79 CSNK2A1 (0.48) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL9288889 0.79 GPR84 (0.45) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL9887640 0.79 AXL (0.42) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL1474051 0.75 RIPK1 (0.43) AXLCDK8AHRF7LTA4H
SCHEMBL25613025 0.75 FEN1 (0.37) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL24005526 0.75 CDK8 (0.35) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL29957381 0.75 CYP2A6 (0.41) AXLPRKCICDK8CSNK2A1PIK3CD
SCHEMBL18984392 0.74 GRIN2D (0.41) AXLCDK8CSNK2A1RIPK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025069270-A1 AZAINDOLE COMPOUND AND MEDICINE 日本新薬株式会社 2025-04-03 WO disclosed
WO-2025070627-A1 AZAINDOLE COMPOUND AND MEDICAL DRUG 日本新薬株式会社 2025-04-03 WO disclosed
CN-103228656-B 3-substituent-6- (pyridylmethoxy) -pyrrolopyridine compounds ELI LILLY AND CO. (US) 2015-09-30 CN disclosed
EP-2646437-B1 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS LILLY CO ELI (US) 2014-09-03 EP disclosed
EP-2646437-B1 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS LILLY CO ELI (US) 2014-09-03 EP disclosed
US-8778946-B2 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds ELI LILLY AND COMPANY (US) 2014-07-15 US disclosed
US-8778946-B2 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds ELI LILLY AND COMPANY (US) 2014-07-15 US disclosed
US-8778946-B2 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds ELI LILLY AND COMPANY (US) 2014-07-15 US disclosed
US-20130225602-A1 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-08-29 US disclosed
US-20130225602-A1 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-08-29 US disclosed
US-20130225602-A1 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225602-A1 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS PARK7, SNCA, PINK1 AXL 4134/4885PRKCI 2794/4885CDK8 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.